Active ingredient shortage puts Bristol-Myers Squibb cancer drug on backorder

The Food and Drug Administration reported a shortage of Bristol-Myers Squibb's cancer drug Etopophos as of Sept. 16.

Etopophos is used to treat testicular cancer and small cell lung cancer. The drug is on backorder due to a raw materials shortage of one of the drug's active ingredients.

New York City-based Bristol-Myers Squibb is working to resolve the issue as soon as possible and expects the drug to be available again September 2017.

More articles on supply chain:

Jimmy Kimmel's EpiPen joke calls out high drug prices at Emmys
Ohio police race through anti-overdose drug supply
Sarepta's muscular dystrophy drug to cost $300k a year

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars